Versant Ventures commits $30m to Matterhorn Biosciences

Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.

5 August 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles